Mycobacterium ulcerans disease; Buruli ulcer

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 4, 1999, Pages 337-340

  Thangaraj, Harry S ^a   Evans, Mark R W ^a   Wansbrough Jones, Mark H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BCG; Buruli ulcer; Epidemiology; Histology; Mycobacterium ulcerans; Toxin (mycolactone); Treatment

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; CLARITHROMYCIN; DAPSONE; RIFAMPICIN; STREPTOMYCIN;

CLINICAL FEATURE; DEBRIDEMENT; HISTOLOGY; HUMAN; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; RECURRENT DISEASE; SHORT SURVEY; SKIN ULCER; SPLIT THICKNESS SKIN GRAFT;

EID: 0032874353     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90104-9     Document Type: Review

References (35)

1. Adjei, O., Evans, M. R. W. & Asiedu, A. (1998). Phenytoin in the treatment of Buruli ulcer. Transactions of the Royal Society of Tropical Medicine and Hygiene, 92, 108-109.
2. Aguiar, J., Domingo, M.-C., Guedenon, A., Meyers, W., Stenou, C. & Portaels, F. (1997). L'ulcère de Buruli, une maladie mycobactérienne importante et en recrudescence au Bénin. Bulletin des Seances Academie Royale des Sciences d'Outre-Mer, 43, 325-358.
3. Asiedu, K. & Etuaful, S. (1998). Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. American Journal of Tropical Medicine and Hygiene, 59, 1015-1022.
4. Barker, D. J. P. (1973). Epidemiology of Mycobacterium ulcerans infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 67, 43-47.
5. Fenner, F. (1957). Homologous and heterologous immunity in infections of mice with Mycobacterium ulcerans and Mycobacterium balnei. American Review of Tuberculosis and Pulmonary Disease, 76, 76-89.
6. George, K. M., Barker, L. P., Welty, D. M. & Small, P. L. (1998). Partial purification and characterisation of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infection and Immunity, 66, 587-593.
7. George, K. M., Chatterjee, D., Gunawardana, G., Welty, D., Hayman, J., Lee, R. & Small, P. L. C. (1999). Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science, 283, 854-857.
8. Glynn, P. J. (1972). The use of surgery and local temperature elevation in Mycobacterium ulcerans infection. Australian and New Zealand Journal of Surgery, 41, 312-317.
9. Havel, A. & Pattyn, S. R. (1975). Activity of rifampicin on Mycobacterium ulcerans. Annales de la Société Belge de Médecine Tropicale, 55, 105-108.
10. Hockmeyer, W. T., Krieg, R. E., Reich, M. & Johnson, R. D. (1978). Further characterisation of Mycobacterium ulcerans toxin. Infection and Immunity, 21, 124-128.
11. Krieg, R. E., Hockmeyer, W. T. & Connor, D. H. (1974). Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Archives of Dermatology, 110, 783-788.
12. Lucas, S. B. (1989). Mycobacteria and the tissues of man. In: The Biology of the Mycobacteria, Volume 3, Clinical Aspects of Mycobacterial Disease, Ratledge, C., Stanford, J. & Grange, J. M. (editors). London: Academic Press, pp. 107-176.
13. Lunn, H. F. & Rees, R. J. W. (1964). Treatment of mycobacterial skin ulcers in Uganda with a rhimophenazine derivative (B663). Lancet, i, 247-249.
14. MacCallum, P., Tolhurst, J. C., Buckle, G. & Sissons, H. A. (1948). A new mycobacterial infection in man. Journal of Pathology and Microbiology, 60, 93-122.
15. Marston, B. J., Diallo, M. O., Horsburgh, C. R. Jr, Diomande, I., Saki, M. Z., Kanga, J. M., Patrice, G., Lipman, H. B., Ostroff, S. M. & Good, R. C. (1995). Emergence of Buruli ulcer disease in the Daloa region of Côte d'Ivoire. American Journal of Tropical Medicine and Hygiene, 52, 219-224.
16. Meyers, W. M., Shelly, W. M., Connor, D. H. & Meyers, E. K. (1974). Human Mycobacterium ulcerans infections developing at sites of trauma to skin. American Journal of Tropical Medicine and Hygiene, 23, 919-923.
17. Mitchell, P. J., Jerett, I. V. & Slee, K. J. (1984). Skin ulcers caused by Mycobacterium ulcerans in Koalas near Bairnsdale, Australia. Pathology, 16, 256-260.
18. Ouoba, K., Sano, D.,Traore, A., Ouedraogo, R., Sakande, B. & Sanou, A. (1998). Buruli ulcer in Burkina Faso: apropos of 6 cases. La Tunisie Medicale, 76, 46-50.
19. Pattyn, S. R. & Royackers, J. (1965). Traitment de l'infection expérimentale de la souris par Mycobacterium ulcerans et Mycobacterium balnei. Annales de la Société Belge de Médecine Tropicale, 45, 31-38.
20. Pimsler, M., Sponsler, T. A. & Meyers, W. M. (1988). Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. Journal of Infectious Diseases, 157, 577-580.
21. Portaels, F. (1998). Basic microbiology. Abstracts from the Conference on Buruli Ulcer Control and Research, Yamoussoukro, Cote d'Ivoire, pp. 11-16.
22. Portaels, F., Fonteyne, P. A., De Beenhouwer, H., De Rijk, P., Guedenon, A., Hayman, J. & Meyers, W. M. (1996). Variability in the 3′ end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origins of isolates. Journal of Clinical Microbiology, 34, 962-965.
23. Portaels, F., Traore, H., De Ridder, K. & Meyers, W. M. (1998). In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrobial Agents and Chemotherapy, 42, 2070-2073.
24. Portaels, F., Elsen, P., Guimaraes-Peres, A., Fonteyne, P. & Meyers, W. M. (1999). Insects in the transmission of Mycobacterium ulcerans infection. Lancet, 353, 986.
25. Read, J. K., Heggie, C. M., Meyers, W. M. & Connor, D. H. (1974). Cytotoxic activity of Mycobacterium ulcerans. Infection and Immunity, 9, 1114-1122.
26. Revill, W. D. L., Morrow, R. H., Pike, M. C. & Ateng, J. (1973). A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet, ii, 873-877.
27. Ross B. C., Marino, L., Oppedisano, F., Edwards, R., Robins-Browne, R. M. & Johnson, P. D. (1997a). Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. Journal of Clinical Microbiology, 35, 1696-1700.
28. Ross, B. C., Johnson, P. D., Oppedisano, F., Marino, L., Sievers, A., Stinear, T., Hayman, J. A. & Veitch, M. A. (1997b). Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Applied and Environmental Microbiology, 63, 4135-4138.
29. Saito, S. & Karaki, H. (1996). A family of novel actin-inhibiting marine toxins. Clinical and Experimental Pharmacology and Physiology, 23, 743-746.
30. Sharif, A. A. (1991). The toxicity of Mycobacterium ulcerans. PhD Thesis, University of London, UK.
31. Stanford, J. L. (1983). Immunologically important constituents of mycobacteria: antigens. In: Biology of the Mycobacteria, Volume 2, Ratledge, C. & Stanford, J. (editors). London: Harcourt Brace Jovanovich, pp. 85-127.
32. Stanford, J. L. & Phillips, I. (1972). Rifampicin in experimental Mycobacterium ulcerans infection. Journal of Medical Microbiology, 5, 39-45.
33. Uganda Buruli Group (1969). BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). Lancet, i, 111-115.
34. Uganda Buruli Group (1970). Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group. British Medical Journal, 2, 390-393.
35. Uganda Buruli Group (1971). Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 65, 763-775.